article thumbnail

After IPO fails, imaging agent developer Telix Pharmaceuticals raises $429M via debt

Radiology Business

The Melbourne, Australia-based radiopharmaceutical firm plans to use the proceeds to accelerate development of products in its theranostics portfolio

article thumbnail

Eckert & Ziegler and Actinium ink Ac-225 agreement

AuntMinnie

Eckert & Ziegler has entered into an agreement with Actinium Pharmaceuticals to supply the firm with the radioisotope actinium-225 (Ac-225). Actinium will continue developing its lead radiopharmaceutical product Actimab-A, as well as additional early and late-stage development candidates for both U.S.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Telix acquires assets targeting FAP in nuclear medicine

AuntMinnie

Telix Pharmaceuticals is expanding its theranostic pipeline with newly acquired assets targeting fibroblast activation protein (FAP) in nuclear medicine.

article thumbnail

Blue Earth Diagnostics inks Posluma deal with Sinotau Pharmaceutical

AuntMinnie

Blue Earth Diagnostics and Sinotau Pharmaceutical have signed an agreement to distribute Blue Earth's Posluma (flotufolastat F-18) PET radiotracer in China.

article thumbnail

FDA approves Lutathera for some pediatric patients

AuntMinnie

Food and Drug Administration (FDA) has approved Novartis' Lutathera (lutetium-177 [Lu-177]) DOTATATE radiopharmaceutical for treatment of pediatric patients who are 12 years old and older with somatostatin receptor (SSTR)-positive gastroentropancreatic neuroendocrine tumors (GEP-NETs).

article thumbnail

RefleXion Acquires Global Rights to Radiopharmaceutical Molecule from 3B Pharmaceuticals to Treat High Unmet Need Cancers

Imaging Technology

a therapeutic oncology company and 3B Pharmaceuticals (3BP) GmbH, a biotechnology company developing targeted radiopharmaceutical drugs and diagnostics for cancer detection and treatment, announced an exclusive licensing agreement for RefleXion to develop and commercialize a specific 3BP molecule to direct its SCINTIX biology-guided radiotherapy.

article thumbnail

NorthStar manufactures Cu-67 for Clarity Pharmaceuticals

AuntMinnie

facility NorthStar produces first Mo-99 batch at new facility NorthStar and Inhibrx ink deal on radiopharmaceutical development NorthStar completes construction of Mo-99 production facility Read more on AuntMinnie.com Related Reading: NorthStar appoints new president/CEO NorthStar installs accelerator at its new Wisc.